PCI and clopidogrel: Antiplatelet responsiveness and patient characteristics

Acta Cardiologica

Volumn 66, Issue 3, 2011, Pages 330-340

  Grdinic, Aleksandra ^a   Vojvodic, Danilo ^b   Djukanovic, Nina ^c   Colic, Mirko ^d   Grdinic, Aleksandar G ^e   Ignjatovic, Vladimir ^f   Majstorovic, Ivana ^b   Ilic, Vesna ^b   Magic, Zvonko ^b   Obradovic, Slobodan ^b   Ostojic, Miodrag ^c   Dolijanovic, Slavica Pavlov ^g  

^a University Clinical Hospital Center Dr DragisaMisovic Dedinje   (Serbia)

^b UNIVERSITY OF DEFENCE   (Serbia)

^c CLINICAL CENTER OF SERBIA   (Serbia)

^d Institute for Cardiovascular Diseases Dedinje   (Serbia)

^e UNIVERSITY OF MONTENEGRO   (Montenegro)

^f CLINICAL CENTRE KRAGUJEVAC   (Serbia)

^g INSTITUTE OF RHEUMATOLOGY   (Serbia)

Author keywords

Aspirin; Clopidogrel; Responsiveness; Stent; Vasodilatator stimulated phosphoprotein (VASP) assay

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; VASODILATOR STIMULATED PHOSPHOPROTEIN; ACTIN BINDING PROTEIN; ANTITHROMBOCYTIC AGENT; CELL ADHESION MOLECULE; DRUG DERIVATIVE; PHOSPHOPROTEIN; TICLOPIDINE; VASODILATOR-STIMULATED PHOSPHOPROTEIN;

ADULT; AGED; ARTICLE; CORONARY STENT; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; ELECTIVE SURGERY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PATIENT MONITORING; PERCUTANEOUS CORONARY INTERVENTION; THERAPY RESISTANCE; THROMBOCYTE FUNCTION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; DRUG COMBINATION; DRUG EFFECT; DRUG RESISTANCE; HEART INFARCTION; MIDDLE AGED; PILOT STUDY; PROSPECTIVE STUDY; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

ADULT; AGED; ANGIOPLASTY, BALLOON, CORONARY; CELL ADHESION MOLECULES; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; MYOCARDIAL INFARCTION; PHOSPHOPROTEINS; PILOT PROJECTS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; PROSPECTIVE STUDIES; THROMBOSIS; TICLOPIDINE;

EID: 79958053995     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: 10.2143/AC.66.3.2114133     Document Type: Article

References (35)

1. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, Rumsfeld JS. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301: 937-944.
2. Lordkipanidzé M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparasion of six major platelet function tetsts to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007; 28: 1702-1708.
3. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Jukema JW, Huisman MV. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J 2007; 154: 221-231.
4. Lev EI, Patel RT, Maresh KJ, Guthikonda S, Granada J, DeLao T, Bray PF, Kleiman NS. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 2006; 47: 27-33.
5. Ivandic BT, Giannitsis E, Schilick P, Staritz P, Katus HA, Hohlfeld T. Determination of aspirin responsiveness by use of whole blood platelet aggregometry. Clin Chem 2007; 53: 614-619.
6. Ivandic BT, Schilick P, Staritz P, Kurz K, Katus HA, Giannitsis E. Determination of clopidogrel resistance by whole blood platelet aggregometry and inhibitors of the P2Y12 receptor. Clin Chem 2006; 52: 383-388.
7. Tantry US, Blinden KP, Gurbel PA. Resistance to antiplatelet drugs current status and future research. Expert Opin Pharmacother 2005; 6: 2027-2045.
8. Gurbel PA, Blinden KP, Hayes KM, Yoho JA, Herzog WR, Tantry US. The relation of dosing to clopidogrel responsivness and the incidence of high post treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 2005; 45: 1392-1396.
9. Lepantalo A, Virtanen KS, Heikkila J, Wartiovara U, Kassila R. Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions. Eur Heart J 2004; 25: 476-483.
10. Snoep JD, Hovens, Eikenboom MM, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 167: 1593-1559.
11. Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, Bassi AK, Tantry US. Platelet reactivity in patients and recurrent events post stenting results of the PREPARE POST STENTING Study. J Am Coll Cardiol 2005; 46: 1820-1826.
12. Greenland P, Reicher-Reiss H, Goldbourt U, Behar S. In-hospital and 1-year mortality in 1524 women after myocardial infarction comparison with 4315 men. Circulation 1991; 83: 484-491.
13. Chandra NC, Ziegelstein RC, Rogers WJ, Tiefenbrunn AJ, Gore JM, French WJ, Rubison M. Observations of the treatment of women in the United States with myocardial infarction: A report from the National Registry of Myocardial Infarction I. Arch Intern Med 1998; 158: 981-988.
14. Hochman JS, Tamis JE, Thompson TD, Weaver WD, White HD, Van de Werf F, Aylward P, Topol EJ, Califf RM. Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators. N Engl J Med 1999; 341: 226-232.
15. Malacrida R, Genoni M, Maggioni AP, Spataro V, Parish S, Palmer A, Collins R, Moccetti T. A comparison of the early outcome of acute myocardial infarction in women and men. The Third International Study of Infarct Survival Collaborative Group. N Engl J Med 1998; 338: 8-14.
16. Johnson M, Ramey E, Ramwell PW. Sex and age differences in human platelet aggregation. Nature 1975; 253: 355-357.
17. Simon T, Mary Krause M, Cambou JP, Hanania G, Gueret P, Lablanche JM, Blanchard D, Genes N, Danchin N; USIC Investigators. Impact of age and gender on in-hospital and late mortality after acute myocardial infarction: Increased early risk in younger women: results from the French nation wide USIC registries. Eur Heart J 2006; 11: 1282-1288.
18. Montanari CM, Vitoria A, Rossi U, Sala P. Human platelet aggregation curve and oral contraception. Acta Haematol 1979; 61: 230-232.
19. Steinbul SR, Badimon JJ, Bhatt DL, Herbert JM, Luscher TF. Clinical evidence for anti inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. Vasc Med 2007; 12: 113-122.
20. Elsenberg EH, van Werkum JW, van de Wal RM, Zomer AC, Bouman HJ, Verheugt FW, Berg JM, Hackeng CM. The influence of clinical characteristics, laboratory and inflamatory markers on 'high on-treatment platelet reactivity' as measured with different platelet function tests. Thromb Haemost 2009; 102: 719-727.
21. Ferreira IA, Mocking AI, Feijge MA, Gorter G, van Haeften TW, Heemskerk JW, Akkerman JW. Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2006; 26(2): 417-422.
22. Desai AA, Nazak VK, Desai NK. Effect of nifedipine and aspirin on platelet aggregation: A study in hypertensive patients and normal volunteers. Indian J Pharmacol 1995; 27: 167-170.
23. Hung J, Lam JY, Lacoste L, Letchacovski G. Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation 1995; 192(9): 2432-2436.
24. Jacopo G, Elisabetta V, Silverio S, Massimiliano M, Sergioa B, Grazia AM, Philippe CJ. Identification of platelet hyper-reactivity measured with a portable device immediately after percutaneous coronary intervention predicts in stent thrombosis. Thromb Res 2007; 121(3): 407-412.
25. Boneu B, Destelle G. Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patients. Thromb Haemost 1996; 76(6): 939-943.
26. Angiolillo DJ, Shoemaker SB, Desai B, Yuan H, Charlton RK, Bernardo E, Zenni MM, Guzman LA, Bass TA, Costa MA. Randomized comparison of a high clopidogrel maintained dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 2007; 115: 708-716.
27. von Beckerath N, Kastrati A, Wieczorek A, Pogatsa-Murray G, Sibbing D, Graf I, Schömig A. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J 2007; 28: 1814-1819.
28. Angiolillo DJ, Costa MA, Shoemaker SB. Functional effects of high clopidogrel maintance dosing in patients with inadequate platelet inhibition on standard dose treatment. Am J Cardiol 2008; 101: 440-445.
29. Fontana P, Senouf D, Mach F. Biological effect of increased maintained dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19 2 allele on clopidogrel responsiveness. Thromb Res 2008; 121: 463-468.
30. Antitrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
31. Pettersen AA, Seljeflot I, Abdelnoor M, Arnesen H. Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (Aspirin Non Responsiveness and Clopidogrel End Point Trial) design. Scand Cardiovasc J 2004; 38: 353-356.
32. Geiger J, Teichmann L, Groddmann R, Aktas B, Steigerwald U, Walter U, Schinzel R. Monitoring of clopiodgrel action: comparison of methods. Clin Chem 2005; 51: 614-619.
33. Ivandic BT, Sausemuth M, Ibrahim M, Giannitsis E, Gawaz M, Katuss HA. Dual antiplatelet resistance is a risk factor for cardiovascular events after percutaneous coronary intervention. Clin Chem 2009; 55(6): 1171-1176.
34. Guha S, Sardar P, Guha P, Roy S, Mookerjee S, Chakrabarti P, Deb PK, Chaudhuri U, Deb S, Karmakar R, Dasgupta AK, Lahiri P. Dual antiplatelet drug resistance in patients with acute coronary syndrome. Indian Heart J 2009; 61: 86-73.
35. Hobson AR, Qureshi Z, Banks P, Curzen NP. Effects of clopiodgrel on aspirin specific pathways of platelet inhibition. Platelets 2009; 20(6): 386-390.